Terry Pirovolakis
 | The topic of this article may not meet Wikitia's general notability guideline. |
Terry Pirovolakis | |
|---|---|
| Add a Photo | |
| Born | 1979 |
| Nationality | Canadian |
| Occupation |
|
Terry Pirovolakis (born 1979) is a Canadian technologist and biotech leader focused on developing treatments for ultra-rare disorders. He has spent much of his career in IT, building call centers and CRM systems for Fortune 500 companies worldwide. In 2019, his youngest son, Michael, was diagnosed with SPG50, an ultra-rare disease. In response, Terry and his family founded CureSPG50 to raise funds for research and treatment for this condition, which affects fewer than 200 children globally.[1] Within three years, they raised $4.5 million and developed a treatment for Michael and others with SPG50. Following this achievement, Terry founded Elpida Therapeutics SPC, a biotech company run as a non-profit, dedicated to providing gene therapies to children in need worldwide.
References
- ↑ Roumeliotis, Ioanna; Mancini, Melissa. "'A race against time': Toronto family tries to raise $3M to treat son's rare genetic disorder".
External links
This article "Terry Pirovolakis" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.